Takeover Fever in the Pharma Industry

Finance Articles | February 5, 2009

There's renewed enthusiasm in the pharmaceutical industry and this is good for the marketplace. The first big story this year was Pfizer's (NYSE/PFE) takeover bid for Wyeth (NYSE/WYE) -- and the fever is beginning to spread to other names in the industry.

Bristol-Myers Squibb (NYSE/BMY) is often referred to by industry insiders as one of the most desirable pharmaceutical companies for a takeover. The rumor is now that the French company Sanofi-Aventis (NYSE/SNY) is gearing up to buy some more U.S. assets. Both of these companies already have a strong working relationship with each other, as they split revenues from the well-known blood thinner "Plavix," which is the world's second best selling drug.

I wrote before that the pharmaceutical industry is ripe for consolidation in the current economic environment, because so many brand name drugs are coming off of patent over the next few years. Competition from generic drug makers is going to be fierce and it will be very difficult for the large industry players to grow revenues and earnings. So, with this reality, there isn't much else they can do but merge with each other. It's the old adage: if you can't beat them, then you might as well join them.

Investor enthusiasm for large-cap pharmaceutical companies tends to occur in waves. The only thing that keeps investors interested throughout the volatile product development cycle is fairly strong dividends among most companies. Currently, Bristol-Myers Squibb is yielding over five percent and Pfizer is now yielding just over eight percent (the stock is down because of its takeover bid for Wyeth).

You can easily make compelling arguments that the outlook for large-cap pharmaceutical companies is either great or lousy. The aging population is a solid demographic argument for the industry, but the product development and marketing costs are so large that earnings growth is a real challenge.

I'd have one or two large-cap pharmaceutical companies as part of a well-balanced equity portfolio. Investor enthusiasm for the industry is turning around right now. Merck (NYSE/MRK) just reported earnings that beat consensus estimates and so did Schering-Plough(NYSE/SGP). Without the dividends, however, these companies would be significantly less attractive as an investment.

Profit Confidential

---

http://www.profitconfidential.com/

LOMBARDI PUBLISHING CORPORATION
News, Analysis, and Information Services Since 1986.
One Million Customers in 141 Countries.

Lombardi Publishing Corporation
Financial Publications Division
350 Fifth Avenue, Suite 3304
New York, NY 10118-3304

---

Copyright 2008; Lombardi Publishing Corporation. All rights reserved. No part of this e-newsletter may be used or reproduced in any manner or means, including print, electronic, mechanical, or by any information storage and retrieval system whatsoever

, without written permission from the copyright holder.

Source: Free Articles from ArticlesFactory.com

ABOUT THE AUTHOR

Mitchell Clark, B. Comm., Senior Editor at Lombardi Financial, specializes in small-cap stocks. He’s the editor of a variety of popular Lombardi Financial newsletters, such as Penny Stock Reporter, Micro-Cap Stocks, and Monster Profits. Mitchell, who has been with Lombardi Financial for eleven years, is currently authoring a book on how to pick small-cap stocks for maximum profits. Prior to joining Lombardi, Mitchell was a stock broker for a division of one of the largest financial institutions in North America.